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Th  e early, accurate diagnosis and risk stratiﬁ  cation  of 
sepsis remains an important challenge in the critically ill. 
Despite signiﬁ  cant improvements in clinical care, sepsis 
continues to be a lethal and expensive condition with 
mortality rates approaching 20 to 30% [1-4]. While 
clinicians typically incorporate elements of history, phy-
si  cal examination, laboratory and radiographic testing, 
no single accepted biomarker, combination of biomarkers 
or clinical prediction rule is used to aid in diagnosis and 
risk stratiﬁ   cation [5,6]. Since traditional biomarker 
strate  gies whereby one measures the concentration of 
circulating proteins have not yielded a deﬁ  nitive  bio-
marker or set of biomarkers for sepsis, focus is shifting 
towards strategies that improve assessment capabilities. 
Th   e overall objective is to facilitate early and appropriate 
therapeutic intervention, improve triage decisions, 
provide a means to follow response to therapy, establish 
new therapeutic targets, and/or provide ways to identify 
patients amenable to tailored therapies.
Technological advancements, along with the informa-
tion generated through the human genome project, have 
positioned systems biology at the forefront of biomarker 
discovery. Th  is has facilitated approaches that may not 
only yield an improved insight into complicated sepsis 
pathophysiology, but may also identify unexplored 
pathways [7,8]. Over the past decade, technologies focus-
ing on DNA, gene expres  sion, gene regulatory mechanisms, 
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Taken together, a systems biology approach links these 
indi vidual  ﬁ  elds of study. Systems biology refers to the 
integration and analysis of complex datasets derived from 
multiple facets of the body’s signaling and response 
pathways (that is, geno  mics, transcriptomics, proteomics, 
and metabolo  mics). Th   e science of biomarkers discovery 
has substantially evolved, with focused ﬁ  elds of study on 
each part of the lifecycle of biologic signaling and 
response. While the ‘omics technologies’ have been avail-
able in varying capa  cities for well over a decade (reviewed 
in [9-18]), advances in technology are continually in-
creas  ing the feasi  bility and accessibility, while decreasing 
the costs. Th  e objective of this paper is to provide the 
reader with an overview and understanding of these 
approaches and techniques that are at the forefront of 
sepsis research.
Genomics
Genomics (Figure 1, target 1) is the study of the entire 
complement of genetic material of an individual. In 2003, 
after 13 years, the international human genome project 
completed its task of sequencing the 3  billion  bp of 
human genomic DNA, estimating a total of ~28,000 to 
34,000 genes. Th  is laid the foundation for functional 
genomics, genomics medicine, bioinformatics and systems 
biology to investigate functions and regulatory mecha-
nisms. Th   e sequencing of the human genome has moved 
systems biology into the forefront of biomarker discovery. 
In sepsis, genomics focuses primarily on genomic varia-
tion analysis [19].
Genetic variation analysis
Background
Th   e notion that genetics plays an important role in sepsis 
is not new. In 1988 Sorensen and colleagues conducted a 
study of adoptees in Denmark, focusing on death from all 
causes. Th   e study found that if a biological parent died of 
infection before the age of 50 years, the child had a 5.8 
relative risk of also dying from infection [20]. In fact, 
there is a much higher heritability of death due to infec-
tion than due to cancer or heart disease. Th  is suggests 
that the genetics of sepsis is an important factor in 
determining outcome and makes genomics research 
particularly interesting.
Th   e primary approach for studying human genetics in 
relation to disease is to analyze genetic variations called 
single nucleotide polymorphisms (SNPs). A SNP results 
from a single base mutation in the DNA sequence and 
has a frequency of 1% or more in the population. Large-
scale SNP discovery projects such as the HapMap have 
identiﬁ   ed that a comparison of two chromosomes 
between any two individuals will generally reveal, on 
average, 5 to 10 million common SNPs across the genome 
[21,22]. Th  e large number of SNPs identiﬁ  ed has led to 
the development of an SNP database  – the dbSNP, 
established by the National Center for Biotech  nology 
Information [23]. In February 2013 the dbSNP contained 
53  million unique human SNPs. Th  e USCS Genome 
browser lists results from genome-wide associa  tion 
studies (GWAS) and has developed an integrated map of 
genetic variation from 1,092 human genomes as of March 
2013 [24,25].
Th  e  eﬀ  ort to ﬁ  nd genetic variants that are responsible 
for susceptibility to sepsis has been primarily gene 
association studies in case–control or cohort studies. In 
2010, a large case–control study including over 8,000 
subjects found a genetic association between ﬁ  ve SNPs in 
the gene coding for IL-2 with increased susceptibility to 
bacteremia, malaria and tuberculosis [26]. Th  e overall 
risk of one of these infectious diseases was increased to 
81% in persons with four or more IL-2-speciﬁ  c SNPs. 
Such studies often rely on already known genetic varia-
tions from the HapMap database. However, due to the 
ever increasing dbSNP database and the fact that geno-
typing technology has become less expensive, focus has 
shifted towards GWAS [27].
GWAS simultaneously probe all segments of the 
genome for evidence of association between a known 
SNP and disease by comparing diseased and nondiseased 
populations to identify SNPs that are more prevalent in 
the diseased state. GWAS have thus far uncovered 
>800  SNP associations for more than 150 disease and 
other traits [28]. For these hypothesis-generating studies, 
DNA microarrays or whole genome sequencing are often 
used because high throughput is feasible, and a priori 
selection of speciﬁ  c SNPs is not required. DNA micro-
arrays identify pathways and associations in an extremely 
eﬃ   cient fashion (Figure 2). DNA microarrays are more 
comprehensive than PCR methods because PCR uses 
primers that the investigator needs to specify before the 
analysis is run. Furthermore, PCR is only capable of 
analyzing hundreds of SNPs as compared with millions 
when using DNA microarrays.
GWAS provide the researcher with information about 
whether a SNP is present or not. GWAS do not oﬀ  er any 
information about gene regulation or disease progression. 
Th   e ChIP-on-chip technique combines chromatin 
immuno  precipitation (the ChIP) with DNA microarray 
technology (the chip). Chromatin immunoprecipitation 
refers to the technique of precipitating a protein antigen 
from a solution using an antibody that speciﬁ  cally binds 
to that particular protein. Th  is technique is used to 
investigate interactions between proteins and DNA. Th  e 
proteins are generally those operating in the context of 
chromatin. Th   e overall goal of ChIP-on-chip is to localize 
protein-binding sites that may help identify functional 
elements in the genome.
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Several SNPs in genes coding for the innate immune 
system have been identiﬁ  ed as playing a role in patho-
physiology and outcomes in severe sepsis or septic shock 
[29-36]. One study found that when administering 
activated protein C (Xigris™; Eli Lilly and Company, 
Indianapolis, IN, USA) a polymorphism at position 
–1,641 AA in the promoter region coding for protein C 
was associated with decreased survival, in  creased organ 
dysfunction and increased systemic inﬂ  am  mation  in 
severe sepsis [37]. Even though Xigris™ has been 
withdrawn by the manufacturer, this therag  nostic 
Figure 1. Central workfl  ow from gene activation to protein metabolites in response to insults such as infection. Numbers denote diff  erent 
targets for diagnostic approaches: 1, epigenomics (methylation variable positions) and genomics (SNPs); 2, transcriptomics (mRNA and miRNA); 
3, proteomics; and 4, metabolomics. The central workfl  ow in molecular biology is that, upon gene activation, DNA is transcribed into mRNA and is 
then translated into proteins. DNA expresses its information by a process called transcription. In this process, segments of the DNA sequence are 
used as templates for the synthesis of shorter molecules of the closely related molecule RNA. This molecule consists of sequences of nucleotides 
faithfully representing a part of the cells genetic information. The transcription results in pre-mRNA, which through an additional splicing process 
produces a mature single strand of complementary RNA, mRNA. mRNA functions as an intermediate in the transfer of genetic information, mainly 
guiding the synthesis of proteins according to the genetic instructions stored in the DNA. Once mRNA is produced and transported out of the 
nucleus, the information present in the mRNA is used to synthesize a protein by the process called translation. This protein synthesis is performed in 
the cytosol of the cell by the ribosome, the workhorse of protein biosynthesis. mRNA is pulled through the ribosome and the nucleotide sequence 
is translated into an amino acid sequence, adding each amino acid to a growing polypeptide chain that constitutes a protein. miRNA can alter 
this step by binding to the mRNA, resulting in additional regulation of the mRNA expression. miRNA is complementary to a part of one or more 
mRNAs. While degradation of miRNA-targeted mRNA is well documented, whether or not translational repression is accomplished through mRNA 
degradation, translation inhibition or a combination of the two is hotly debated. After the polypeptide chain is produced, it folds up into its unique 
three-dimensional conformation, which is necessary in order to be useful to the cell. The result is the fi  nal product, a mature protein that is released 
into the bloodstream where it will have its eff  ects [98].
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respond to a given therapy are targeted – is certainly a 
likely future path forward. Th   ere are a number of other 
examples of the importance of SNPs in infection [31-
33,38]. For example, in a 176-patient human trial in 
sepsis, a speciﬁ  c SNP at the –308 position in the TNFα 
promoter region was associated with elevated TNFα 
expression in vitro and in vivo, and conferred to a 1.5-fold 
to fourfold increased mortality in studies of septic shock. 
Th   e association between gene polymorphisms and 
mortality awaits large-scale validation but there is a 
strong support for the inclusion of genotyping when 
designing sepsis trials [19,39,40].
Advantage
Th  e primary attraction of genomic approaches for gene 
identiﬁ   cation is that one may study the genome to 
determine how genetic predisposition inﬂ  uences disease 
acquisition and response. Th  e GWAS approach can 
elucidate the molecular basis for disease without any 
prior understanding of the biology underlying the 
disease. Th   is unbiased genome level approach is particu-
larly interesting in a heterogeneous syndrome such as 
sepsis where the underlying pathophysiology is poorly 
understood.
Limitations
In sepsis research, the focus is on the elements that cause 
disease and alter phenotypes through alteration of 
molecular function. Th  ere are challenges to identifying 
such functional variants. Earlier studies have primarily 
evaluated SNPs in regulatory or coding regions, which 
alter expression of a gene or produce an altered protein 
structure that may be dysfunctional [41]. Th  is  approach 
may be oversimpliﬁ  ed and ignores the fact that other 
SNPs might alter outcome – SNPs that we do not yet 
know the exact function of. Furthermore, our under-
standing of how SNPs disrupt molecular function is 
poorly understood [42]. Without a complete under-
standing of the regulation of transcription of a gene, an 
association study strategy based on the functional 
plausibility of single SNPs may overlook polymorphisms 
essential for the expression of genes [43]. Indeed, it seems 
that the major obstacle is an information gap, not simply 
a technology gap.
Epigenetics
Gene activity is regulated by a variety of mechanisms, 
known as epigenetics. Th   ese mechanisms rely on rever  si-
ble modiﬁ  cations of DNA (most commonly DNA methy-
lation and histone modiﬁ  cation) that aﬀ  ect gene expres-
sion without altering the DNA sequence. Th  e  distribution 
of these modiﬁ   cations may not only be speciﬁ   c to a 
particular organism or a particular tissue, but may also 
mark speciﬁ  c disease states. Th  e epigenome (Figure  1, 
target 1) is the distribution of epigenetic regulation. Th  e 
epigenome is not static, like the genome, but changes in 
response to environmental changes, and plays a funda-
mental role in gene expression following environmental 
and extracellular stimuli.
Background
DNA methylation is the biochemical process involving 
addition of a methyl group to the 5-position of the 
cytosine pyrimidine ring or the number-6 nitrogen of the 
adenine purine ring. Th  e changes in DNA methylation 
are often associated with chromosome instability and 
gene repression. Histone modiﬁ   cation is another 
Figure 2. DNA microarrays in genomics. The core principle behind 
DNA microarray technology is hybridization of genomic DNA 
fragments to a fi  xed probe. The collected genomic DNA is amplifi  ed 
and labeled and is then hybridized to a cDNA chip that is loaded 
with various SNPs. The sample DNA will hybridize with greater 
frequency only to specifi  c SNPs associated with that person. Those 
spots on the microarray chip will fl  uoresce with greater intensity. 
The workfl  ow of this entire process is 3 to 5 days depending on the 
technology used.
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function of histones is to package and order the DNA 
into structural units by wrapping the DNA around core 
histones. Huge cata  logues of histone modiﬁ  cations have 
been described but the functional meaning of these are 
not yet fully under  stood. Acetylation of the histones 
probably opens up the DNA and facilitates transcription. 
Speciﬁ  c deacetylases reverse this by closing the DNA, 
making it more condensed and promoting gene 
repression. Methylation of the histones may also activate 
or repress the DNA. Only recently have epigenomic 
proﬁ  ling technologies reached the stage at which large-
scale studies are becom  ing feasible. A variety of both 
array-based and sequen  cing-based methods are available, 
with the choice based on balancing coverage, resolution, 
accuracy, speciﬁ  city, throughput and costs [44].
DNA methylation is detected by the use of bisulﬁ  te 
treatment of DNA. Th   is treatment changes 
unmethylated cytosines to uracil but leaves methylated 
cytosines unchanged. When looking at epigenetic 
changes in the genome, the primary focus is on the CpG 
islands, which are >200 bp stretches of DNA that have a 
signiﬁ   cantly higher frequency of the nucleotides 
cytosine and guanine. Th   ese islands have been found in 
approximately 40% of promoters of human mammalian 
genes [45]. Usually the CpG islands occur near the 
transcription site of genes and are involved in the 
transcriptional regu  lation. Diﬀ  erential  methylation 
hybridization allows the simultaneous determination of 
the methylation levels of a large number of CpG island 
loci [46]. Th  e genome wide study of histone modiﬁ  -
cations is achieved by HPLC (a technique for separating 
DNA or protein molecules by molecular weight and 
conformation) and high-perfor  mance capillary electro-
phoresis (a separation technique that uses narrow-bore 
fused-silica capillaries to separate a complex mixture of 
chemical compounds) [47].
Clinical utility
Th   ere are no major studies of epigenetic modiﬁ  cations in 
sepsis of which we are aware. Several histone modiﬁ  -
cations are demonstrated to diﬀ  erentially regulate sub-
sets of lipopolysaccharide-induced genes. A phosphoryla-
tion of a speciﬁ  c histone (histone 3 at serine 10) may have 
a gene-speciﬁ  c role in NF-κB recruitment [48]. NF-κB is 
a transcriptional regulatory factor and a central partici-
pant in modulating the expression of many of the 
immunoregulatory mediators involved in sepsis. After 
lipopolysaccharide stimulation, the genes encoding for 
several cytokines, including IL-6, undergo phosphoryla-
tion at their promoters. Th  is facilitates NF-κB recruit-
ment and gene induction. DNA methylation is a common 
epigenetic signaling tool that cells use to silence genes 
and thereby regulate gene expression [49].
Advantages
Despite the success of the GWAS, there is still a 
substantial proportion of causality that remains un-
explained. Increasingly evident is that the epigenome is 
highly dynamic and consists of a complex interplay of 
genetic and environmental factors [50]. A method to 
uncover this interplay is the epigenomics equivalent of 
GWAS – epigenome-wide association studies [51]. For 
DNA methylation, technology is now available that is 
directly comparable in resolution and throughput with 
the GWAS chips [51]. Th   e epigenetic equivalent of a SNP 
is DNA methylation at a single site, known as a methy-
lation variable position. Based on simulations assuming 
conservative methylation odds ratios, epi  genome-wide 
association studies should be able to detect associations 
in fewer samples compared with GWAS [51]. For non-
malignant, common complex diseases such as diabetes or 
autoimmunity, the investi  gation of the epigenetic 
component is only beginning.
Limitations
Disease-associated epigenetic variation can be tissue or 
cell speciﬁ  c. All tissues are composed of multiple cell 
types (blood contains more than 50 speciﬁ  c cell types). If 
the disease-associated variation is restricted to a speciﬁ  c 
cell type, then assessing the wrong tissue type (for 
example, the easily accessible leukocyte from circulating 
blood) will miss a target [51]. Furthermore, there is no 
epigenomic equivalent of the HapMap project, which 
helped to elucidate some of the genetic variation in the 
human genome. Since no database exists, we are not yet 
capable of making any statements about the frequency of 
an epigenetic regulation since we do not know the level 
of normal epigenetic variation that exists in human 
populations [51]. Lastly, since epigenetic variation can be 
causal of disease or can arise as a consequence of disease, 
it can be diﬃ     cult to conclusively distinguish between 
disease-driving or passenger epigenetic variants, thus 
making reverse causation a concern [51].
Transcriptomics
Transcriptomics (Figure 1, target 2) is the quantiﬁ  cation 
of messenger RNA levels for a large number of genes in 
speciﬁ   c cells or tissues to measure diﬀ   erences in the 
expression levels of diﬀ  erent genes and the utilization of 
patterns of diﬀ  erential gene expression to characterize 
diﬀ  erent biological states of a tissue. Unlike the genome, 
which is mostly similar for a given cell line, the trans-
criptome responds constantly to external environmental 
conditions and internal conditions, such as sepsis. Th  e 
study of transcriptomics, also referred to as expression 
proﬁ   ling, examines the expression level of mRNAs or 
miRNAs in a given cell population. Th   e transcriptome is 
thus indicative of gene activity and regulation. In 
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thus the same genes. However, not every gene is 
transcriptionally active in every cell; diﬀ  erent cells show 
diﬀ  erent patterns of gene expression [52]. In context, the 
transcriptome is seen as a precursor for the entire set of 
proteins expressed by the genome – the proteome.
Gene expression profi  ling
Background
In 2001, a novel molecular approach using microarrays to 
monitor genome-wide changes in relative mRNA abun-
dance in the host response to infection was described 
[53]. Th  is was the beginning of genome-wide trans-
criptomics as an investigational tool to study sepsis. DNA 
microarrays are a commonly used technique to proﬁ  le 
gene expression as they allow for genome-wide assess-
ments of changes in gene expression by surveying 
expression patterns for tens of thousands of genes in a 
single experiment (Figure 3) [54]. Since its introduction, 
microarray technology has been applied to sepsis by 
several investigators (reviewed in [9]); however, further 
work is needed to advance our understanding and to 
increase the scope of implementation in research.
Another approach to provide a quantitative view of the 
expression of selected genes is multi-gene transcriptional 
proﬁ   ling, which quantiﬁ   es mRNA copy numbers. [55] 
Compared with DNA microarrays that are limited in their 
accuracy and reproducibility, multi-gene transcrip  tional 
proﬁ  ling uses real-time PCR – a method widely regarded 
as the gold standard for nucleic acid quanti  ﬁ  cation [56,57]. 
Compared with DNA microarrays, the results are 
quantitative and, if real-time PCR is employed, the 
turnaround time is short. Real-time PCR lacks the 
discovery breadth of DNA microarrays since it cannot be 
used for a genome-wide scan, but it has the ability to 
rapidly and quantitatively measure hundreds of genes and 
could allow for targeted screening for multiple biomarkers.
Th  e demand for low-cost sequencing has driven the 
development of next-generation sequencing technolo-
gies, such as RNA-seq. Th   is technique does not require 
the sequence information in order to detect and evaluate 
transcripts, and has deep coverage and base-scale reso-
lution. To our knowledge, however, this technique has 
not yet been applied to sepsis research. For many, the 
DNA microarray approach is still the method of choice 
due to lower costs and availability.
Clinical utility
Alterations in transcript/gene abundance in cells such as 
white blood cells and endothelial cells that aﬀ  ect cytokine 
synthesis, cytokine receptor expression, protein synthesis 
regulation and apoptosis have been reported in patients 
with severe sepsis [58]. One whole blood gene expression 
analysis revealed over 500 unique genes that were 
diﬀ   erentially expressed comparing pre-septic patients 
(patients with systemic inﬂ  ammatory response syn  drome, 
who developed clinical sepsis during the study) and 
uninfected patients with systemic inﬂ  ammatory response 
syndrome [59]. In addition to discriminating inﬂ  ammation 
from sepsis, gene expression proﬁ  ling also has been widely 
implemented to identify predictive bio  markers. A recent 
systematic review by Tang and colleagues found that a 
total of 12 cohorts consisting of 784 individuals has been 
investigated using genome-wide expression data [60]. Even 
though the studies had consistent results in terms of 
activation of signal trans  duction cascades and pathogen 
recognition receptors, the studies had highly variable 
changes in inﬂ  ammation-related genes. In a genome-wide 
survey of mRNA expres  sion in 38 patients with septic 
shock, a set of 28  genes that discriminated between 
survivors and nonsurvivors was identiﬁ  ed.  Th  ese genes 
were upregulated between 31 and 714% [61]. In 2010, a 
transcriptional-based stratiﬁ     cation strategy for pediatric 
septic shock was published [62]. Th  is strategy was based 
on 100 gene signatures and gene expression mosaics, and 
provides proof of the concept for the use of gene 
expression data in a clinical setting. Th   e results from the 
ﬁ  rst gene expression proﬁ  l  ing studies are promising and 
are hypothesis generating; however, they await further 
larger scale studies in more generalizable populations.
Advantages
Th  e use of transcriptomics in sepsis has enabled the 
discovery of speciﬁ  c and sensitive transcriptional signa-
tures consistent with activation of pathogen recognition 
receptors in the human cell. Associated alterations in 
signal transduction pathways in sepsis have the potential 
to increase the knowledge of the pathophysiology of 
sepsis. Several gene expression patterns have been 
associated with the early diagnosis of sepsis, and this 
could be exploited to direct early interventions.
Limitations
Genome-level transcriptional studies have found highly 
variable changes in the transcriptional proﬁ   les of genes 
associated with inﬂ   ammation. Indeed, there is a lack of 
consistent patterns in the expression of sepsis markers [63]. 
Th   ere are several possible reasons for this – for example, the 
studies have typically assessed gene expression changes in 
circulating leukocytes, and gene expression changes in 
resident leukocytes in local tissue may be diﬀ  erent. Further-
more most of the studies have not reported leukocyte 
diﬀ  erential, which indeed is important due to the variability.
microRNAs
Background
MicroRNA (miRNA) are small ~22 nucleotide-long non-
coding RNAs that regulate gene expression at the level of 
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target 2). Th  e  eﬀ  ects of miRNAs on gene expression and 
control are generally inhibitory, and the corresponding 
regulatory mechanisms are therefore collectively termed 
RNA silencing. Th  ey are thought to regulate expression 
of protein-coding genes by direct interaction with and 
degradation of mRNA or by inhibition of protein 
translation [64]. Although estimated to represent around 
2% of the genome, miRNA gene products are proposed to 
regulate as many as 92% of the genes in humans [65].
Recent studies also reveal that miRNAs may function 
as mediators of cell-to-cell communication. Th  ere  is  thus 
a possibility that miRNAs are taken up by distant cells to 
regulate gene expression. Since miRNA is involved in 
numerous cellular processes, including cell proliferation, 
diﬀ  erentiation and apoptosis, it is proposed that levels of 
speciﬁ   c miRNAs could serve as novel biomarkers of 
disease. In fact, the regulation of miRNA production may 
provide the human cell with a fast-acting response to 
environmental changes, such as an infection. Since 
miRNA acts on many diﬀ  erent mRNAs simultaneously, 
the miRNA regulation is widespread. Additionally, the 
interaction between miRNA and mRNA may have 
important biologic implications (for example, mRNA 
may be present but miRNA may regulate its activity) – 
such that to properly interpret an mRNA signal, the 
miRNA interaction must be considered. miRNAs hold a 
particularly appeal in the clinical setting because they are 
very stable in both plasma and serum [66,67]. 
Approximately ~20,000 miRNAs are thus far identiﬁ  ed 
and registered in the miRBase – a database that acts as an 
archive of miRNA sequences and annotations.
Clinical utility
Owing to the regulatory role of miRNA on gene expres-
sion, it is not surprising that miRNA expression levels are 
altered in human pathological conditions, due to the 
changes in the transcriptional or post-transcriptional 
regulation and miRNA expression. Indeed, data suggest 
that investigating miRNA expression has potential for the 
identiﬁ   cation of new and early diagnostic as well as 
prognostic and clinical markers [68]. Studies in animals 
Figure 3. DNA microarrays in gene expression analysis. DNA microarrays consist of minuscule amounts of hundreds or thousands of gene 
sequences on a single microscopic plate. To determine which genes are turned on or off   in a cell, mRNA is extracted from whole blood or tissues. 
This mRNA is then labeled using an enzyme to generate a complementary cDNA from mRNA. During this process, fl  uorescent nucleotides are 
attached to the cDNA. The sepsis and the control samples are labeled with diff  erent fl  uorescent dyes. The labeled cDNA is placed on the DNA 
microarray plate. When a given mRNA and its cDNA are present, they bind to the each other, leaving a fl  uorescent tag. The intensity of this 
fl  uorescence indicates how many mRNA have bound to the cDNA. If a particular gene is very active, it produces many copies of mRNA, thus more 
labeled cDNA will bind to the DNA on the microarray plate and generate a very bright fl  uorescent area. If there is no fl  uorescence, then none of the 
mRNA bound to the DNA, indicating that the gene is inactive.
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expressed in many types of immune cells and that 
miRNAs have potentially critical functions in the 
immune system [69-71]. As an example, in vitro proﬁ  ling 
of the human leukocyte response to endotoxemia 
indicated that ﬁ   ve miRNAs consistently responded to 
lipopolysaccharide infusion, four of which were 
downregulated (miR-146b, miR-150, miR-342 and let-7g) 
and one of which was up  regulated (miR-143) [71]. In 
another prospective clinical study enrolling 17 sepsis 
patients and 32 healthy controls, genome-level proﬁ  ling 
by microarray in leukocytes identiﬁ  ed that miR-150 was 
signiﬁ  cantly downregulated in sepsis patients. Further-
more, the levels of miR-150 correlated with the 
Sequential Organ Failure Assessment scores as a measure 
of disease severity.
Advantages
Extracellular miRNAs are remarkably stable in the blood-
stream. Th   is makes probing easy, thus having the poten-
tial to serve as novel biomarkers in sepsis. Furthermore, 
miRNA sequences are evolutionarily conserved and are 
often tissue or pathology speciﬁ  c [72]. Th   is suggests that 
miRNA functions might play an important role in 
regulating networks. Advances in technology platforms 
for miRNA detection such as microarrays and next-
generation sequencing have allowed for the simultaneous 
interrogation of the complete small noncoding RNA 
repertoire. Finally, the interaction between miRNA (coding 
and noncoding) and mRNA may drive functions such 
that interpreting mRNA in the absence of miRNA data 
would be a ﬂ  awed approach.
Limitations
Precisely how miRNAs regulate the expression of 
protein-coding genes is not completely understood, and 
the underlying mechanisms remain an important ques-
tion that will impact on our understanding of gene 
regulation and its alteration in disease.
Proteomics
Proteomics (Figure 1, target 3) is the large-scale discovery 
of proteins. Proteomics conﬁ   rms the presence of the 
protein and provides a direct measure of the quantity 
present.
Background
Compared with traditional protein biomarker technolo-
gies, proteomics uses more discovery enabling techniques 
such as mass spectrometry. Th   e proteome will vary with 
time and distinct requirements, or stresses, that a cell or 
organism undergoes. Proteomics is considered the next 
step in the study of biological systems downstream from 
genomics and transcriptomics. mRNA expression levels 
do not necessarily correlate with protein content [73,74]. 
Th   is noncorrelation is partly due to the fact that not all 
mRNA is translated into proteins and the amount of 
protein produced for a given amount of mRNA depends 
on the gene from which it is transcribed.
Clinical utility
Proteomic methods are divided into expressional pro-
teomics and functional proteomics. Expressional proteo-
mics is the cataloging of the expression of all proteins 
present in cells, tissues or organisms [75]. In biomedical 
application, this comparative approach is usually em-
ployed to identify proteins that are upregulated or 
downregulated in a disease-speciﬁ  c manner for use as 
diagnostic markers. Expressional proteomics analyzes 
proteins that undergo a speciﬁ   c change after a given 
stimulus – such as severe sepsis [76]. As an example, a 
prospective cohort study of liver transplant patients 
assessed which plasma protein peaks were associated 
with postoperative sepsis. Th   e study found that a combi-
nation of ﬁ   ve proteins provided material for useful 
diagnostic biomarkers [77]. A total of 31 patients 
developed sepsis postoperatively and found an area under 
the curve of (0.72, 95% conﬁ   dence interval  = 0.57 to 
0.85), which was similar to procalcitonin (0.68, 95% 
conﬁ  dence interval = 0.53 to 0.82). Another study of 18 
patients with sepsis found diﬀ  erential protein expression 
in survivors versus nonsurvivors [78]. Th  ese plasma 
proteins included both known cytokines as well as a 
group of proteins with unknown functions [78,79].
Functional proteomics is a fundamentally and strate-
gically diﬀ  erent approach. Functional proteomics is an 
emerging research area that focuses on the elucidation of 
biological functions of unknown proteins and the 
deﬁ  nition of cellular mechanisms at the molecular level. 
Due to the number of genome sequencing projects, there 
is an exponential growth in the number of protein sequences 
whose function is still unknown. One obstacle in biology is 
to identify those proteins that participate in speciﬁ  c 
biological processes and to assign a function to each.
Advantages
Plasma is not only the primary clinical specimen but also 
represents the largest version of the human proteome 
present in any sample. Proteomics have several advan-
tages over genomics and transcriptomics. Genetic 
markers reveal only the genotype and hence do not reveal 
anything about the regulation of biological processes in 
response to disease that is expressed at the mRNA or 
protein levels. While mRNA does reveal regulation, it is 
routinely obtained from blood lymphocytes and is not 
well correlated with protein expression [80]. Compared 
with traditional protein biomarker technologies, proteo-
mics have the major advantage of being able to drastically 
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much less restrictive than ELISA and multiplex tech-
nologies in that, theoretically, an unlimited number of 
proteins can be analyzed simultaneously.
Limitations
Every presently known plasma proteomic method still 
only samples a relatively small fraction of the proteome 
that mostly consists of the relatively highly expressed 
proteins [81,82]. Presently used proteomics methods 
mainly sample classical plasma proteins in the range of 
μg/ml to mg/ml, thereby excluding messengers and 
proteins leaking from speciﬁ   c diseased tissue leakage 
products [83]. Th  e abundance of diﬀ   erent proteins in 
blood varies by more than 10 orders of magnitude [79]. 
In fact, attempts to conduct a large-scale characterization 
of the human plasma proteome had been disappointing. 
Th  e Human Proteome Organization has estimated that 
only 10% of the core plasma proteome (estimated to 
contain at least 10,000 proteins [84]) is being eﬀ  ectively 
sampled with current approaches. To identify a peptide, 
it must be detected and sequenced. Due to the over-
whelming presence of peptides derived from the most 
abundant proteins, there is a signiﬁ  cant suppression of 
lower abundance analytes that mask signals of less 
abundant species with similar chemical properties. Th  is 
limits the amount of sample that can be loaded for mass 
spectrometry. Furthermore the currently used mass 
spectrometers have a limited working dynamic range that 
typically spans only three orders of magnitude within a 
single mass spectrum.
Metabolomics
Metabolomics (Figure  1, target  4) is the study of the 
small-molecule end products of cellular processes that 
are the terminal downstream products of the genome, 
and consists of the total complement of all low-
molecular-weight molecules that cellular processes leave 
behind [85].
Background
Metabolomics may provide a viable supplement to 
genomics, transcriptomics and proteomics, to which it is 
intimately coupled. Metabolomics provides information 
furthest downstream from genomics; the key concept is 
that changes in the genome, transcriptome or proteome 
are reﬂ  ected in the metabolome as alterations of metabo-
lite concentration. In recent years, metabolomics has been 
revolutionized. Signiﬁ  cant advances in compu  ta  tional and 
small-molecule detection tools allow the measurement of 
complex metabolic proﬁ  les in biological ﬂ  uids [86].
Metabolomics strategies are divided into two distinct 
approaches, untargeted and targeted. Untargeted meta-
bo  lomics is the comprehensive analysis of all measurable 
analytes in a sample and oﬀ  ers the oppor  tunity for novel 
biomarker discovery. Targeted metabolo  mics measures 
deﬁ   ned groups of chemically charac  terized and bio-
chemically annotated metabolites. Th  e most common 
techniques are high-resolution NMR spectrometry and 
mass spectrometry. NMR spectro  metry exploits the 
behavior of molecules when placed in a magnetic ﬁ  eld, 
allowing the identiﬁ  cation of diﬀ  erent nuclei based on 
their resonant frequency. Spectrometry is limited in their 
ability to identify more than a few small molecules. NMR 
is limited by its relatively insensitivity to very small 
amounts of molecules. Recent advances have been made 
by coupling NMR and mass spectrometry to the 
quantitative measurement of small-molecule metabo  lites 
in patient samples. Th   is quantitative metabolomics 
approach makes it possible to associate changes in 
multiple metabolites to the diagnosis or characterization 
of disease processes. Since metabolomics has the capacity 
of identifying thousands of small molecules, it greatly 
improves our ability to characterize patterns of meta  bo-
lites correlating with disease. Diﬀ  erences in metabolites 
may be predictive of disease severity, and changes over 
time may be useful in characterizing therapeutic res-
ponse, disease progression or clinical outcome [87].
Clinical utility
Metabolomics is positioned at a key point in the 
interpretation of any biological system because of its role 
as the downstream end product. Sepsis is a disease with 
signiﬁ  cant disruption in biochemical homeostasis, and 
initial diﬀ   erences in metabolites may be predictive of 
disease severity and changes over time may be useful in 
characterizing therapeutic response. Recently, metabolo-
mics has been applied in research in sepsis-induced acute 
lung injury [88]. When comparing 13 sepsis-induced 
acute lung injury patients with six healthy controls, the 
study found that distinct metabolites – including glutha-
thione, adenosine, phsophatidylserine and sphingo  mylin – 
diﬀ  ered between the two groups. Not only did this pilot 
study demonstrate the feasibility of plasma H-NMR quanti-
tative metabolomics, but it also justiﬁ  es the continued 
study of this approach. Indeed, larger scale studies are 
needed to verify the potential of metabolomics in sepsis.
Advantages
One of the most important advantages of metabolomics 
is the fact that the metabolome is relatively small 
compared with the other compartments. Around 5,000 
unique molecules are estimated to be present. Metabo-
lites are furthermore sensitive to biological perturbations 
and respond rapidly. Precise measurements are possible 
with available technologies. Lastly, new metabolite bio-
markers may translate well to existing clinical chemistry 
laboratory technologies.
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Untargeted metabolomics strategies are extremely time-
consuming. Furthermore, there are diﬃ   culties in identi-
fy  ing and characterizing unknown small molecules and 
there tends to be a bias towards detection of highly 
abundant molecules [85]. At present, even the combi-
nation of a wide range of analytical tools allows us to see 
only a portion of the total metabolite complement of the 
cell. Furthermore, the physical and chemical properties 
of metabolites are highly divergent. Th  is divergence 
means there is no single extraction process that does not 
incur substantial loss to some of the metabolites, let 
alone a single analytical platform that can measure all of 
the metabolites. A totally comprehensive approach is 
therefore lacking.
Computational analysis in the omics setting
To make sense of the vast amounts of data generated by 
the omics technologies, analytical methodologies and 
tools are key requirements. A crucial step in the disci-
pline of computational analysis is the process of auto-
matically searching large volumes of data for patterns. 
We have entered the so-called p >> n paradigm where the 
number of independent samples is substantially smaller 
than the number of variables (for example, the number of 
genes in an expression proﬁ  le) [89]. In classical research 
settings a few prespeciﬁ  ed null hypotheses are evaluated, 
whereas we are now simultaneously testing thousands of 
hypotheses.
Th  e process of bioinformatics analysis can be divided 
into: data processing and quality control analysis; 
statistical data analysis; biological functions and path-
ways analysis; and data modeling in a system-wide 
context [90]. Data preprocessing and annotation involves 
transformation of raw machine data into readable and 
normalized data. Quality control assessment is a crucial 
ﬁ   rst step in successful data analysis. Before any com-
parisons are performed, one must check that there were 
no problems with sample processing, and that samples 
are of suﬃ     cient quality to be included. After quality 
control, normalization is the next step, which is a trans-
formation of signal values so that diﬀ  erent sample results 
become comparable. For example the normalization for 
microarray data includes background correction, normali-
zation of signal and summarization of signal values of 
probe sets for a transcript. Some of the well-known 
approaches include total intensity normalization [91], 
rank invariant methods [92] and locally weighted linear 
regression [93].
After normalization, genomics or proteomics variables 
from control and diseased groups are compared using 
various statistical models (P value, analysis of variation, 
signal-to-noise ratio, correlation) to identify variables 
that are specially associated with disease condition. To 
reduce false positive results, multiple test-corrected 
statistical methods are employed. Typically these analyses 
yield a long list of variables (for example, gene, proteins, 
meta  bo  lites) that are signiﬁ  cantly altered in the disease 
condition and require further pathways and functional 
enrichment analyses to understand the biological mecha-
nism. Currently, a large number of commercial and 
academic software packages (for example, Ingenuity 
Systems, Cytoscape, GeneGO, Partek) are available for 
this purpose. Th   ese software packages integrate proteins/
genes into biological path  ways based on scientiﬁ  c 
literature by using natural language processors and 
expert human curation [94,95]. Th  ese analyses help in 
understanding the biological eﬀ   ects of genome-level 
variables induced in disease as well as yielding candidate 
pathways for therapeutic inter  vention. Furthermore, 
systems-level modeling of cross  talk or interaction among 
gene/proteins that are altered in disease is routinely 
explored to obtain a coherent systems-level view of the 
underlying biology. Th  is modeling assists in generating 
the scale-free literature-driven networks to determine 
key regulatory nodes of the network that are essential for 
the stability of the network. Disruption of key regu  latory 
nodes is considered to provide the most eﬀ  ective way to 
break a pathophysiological network, thus providing a 
potential method to design gene/protein-based eﬀ  ective 
therapies. In summary, high-level bioinformatics analysis 
will help to identify the key molecules associated with 
disease from thousands of molecules measured in 
genome-level assays.
The development of diagnostics
Th   e discovery of new biomarker targets is merely the ﬁ  rst 
step in the comprehensive approach to developing new 
diagnostics in sepsis. After the biomarker candidate 
discovery, a derivation study is required in order to 
maximize the area under the curve and to choose 
thresholds that can optimize the sensitivity and speci-
ﬁ  city. In this derivation step, the targeted biomarker must 
perform superiorly compared with past biomarkers. Th  en 
follows a validation study, which typically requires the 
measurement of thousands of patient samples. Within 
this phase the analytical evaluation of the selected bio-
markers is assessed. Th  ese include accuracy and pre-
dictability. Lastly, once the clinical evidence of a 
biomarker has been demonstrated, companies will deter-
mine whether the marker is worth pursuing from a 
technical, medical, ﬁ  nancial and legal standpoint.
Future directions
We so far lack a deﬁ  nitive gold standard biomarker that 
distinguishes sepsis from nonsepsis, or that reliably 
predicts outcome. Th  e current literature is ﬁ  lled  with 
numerous single-protein, or occasionally multi-protein, 
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clinical investigation. However, the results have been 
somewhat disappointing, peak in their diagnostic 
accuracy or fail to validate. As this paper describes, there 
are upstream and downstream techniques that may ﬁ  nd 
new and better targets. Th   ese techniques have both the 
potential to increase the spectrum of diagnostic and 
prognostic biomarkers in sepsis, but they also have the 
potential to lead to the discovery of new disease pathways 
(Table 1). Th   is may in turn lead us to improved targets for 
therapeutics. Th  e incorporation of omics into the clinic 
has had successes in other ﬁ  elds. For example, expression 
signatures based on multigene sets are now used 
clinically for breast cancer prediction [96]. Th  e use of 
Table 1. Overview of omics technologies: summary of strengths, limitations and clinical utility for each technology
Omics Strengths  Limitations  Clinical  utility
Genomics
SNP •  Unbiased approach when using 
GWAS
• Cost-eff  ective large-scale genetic 
screening
•  Well-established analysis tools
• Diffi   cult to fi  nd functional and 
structural gene variants
•  Only regulatory or coding regions 
are included
• Theragnostic  approach
• Risk  stratifi   cation
Epigenetics •  Unbiased approach when using 
epigenome-wide association studies
•  Can elucidate the interplay between 
genetic and environmental factors
• Tissue-specifi   c  alterations
• Diff  erent composition of cell types 
during sepsis
•  Frequency of epigenetic changes 
not known
• Reverse  causation
•  Epigenetic signatures for sepsis 
diagnosis and/or prognosis
•  Prediction of therapeutic response
Transcriptomics
Expression profi  ling •  Can generate global view 
transcriptome alterations
•  Provide good coverage of genome
•  Can elucidate alterations in signal 
transduction pathways during sepsis
•  Tissue-specifi  c expression of genes
•  Fails to measure low-expression 
genes with good sensitivity
•  mRNA expression signatures for sepsis 
diagnosis and/or prognosis
•  Prediction of therapeutic response
High-throughput gene 
sequencing (for example, 
RNA-seq) 
• Comprehensive  sequence 
information
• Unbiased  approach
•  Estimates abundance of genes in 
term of copies
•  Tissue-specifi  c expression of genes •  No clinical utility
miRNA •  Stable in blood
•  Suggestive evidence that miRNAs 
play an important role in regulation 
of networks
•  The inclusion of miRNA when 
interpreting mRNA expression
•  Functions not completely 
understood
•  Novel diagnostic and/or prognostic 
biomarkers in sepsis.
•  Necessary for correctly interpretation 
of gene expression
Proteomics •  Provides global or unbiased 
alteration
• Highly  sensitive
•  No need for antibody-based 
technologies for measuring proteins
•  Needs large amount of 
preprocessing or fractions
•  Current instruments unable to 
measure all proteins from complex 
biological fl  uids
• Ineffi   cient quantifi  cation of low 
expression proteins
•  Novel diagnostic and/or prognostic 
biomarkers in sepsis
•  Prediction of therapeutic response
Metabolomics •  Relatively few targets
•  Good translation to existing 
laboratory technology
• Diffi   culty in identifying small 
molecules
•  Diverse physical and chemical 
properties and thus no single 
extraction tool
•  Novel diagnostic and/or prognostic 
biomarkers in sepsis
•  Prediction of therapeutic response
• Disease  progression
GWAS, genome-wide association studies.
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response rates following speciﬁ  c treatment for hepatitis 
C [97].
It is our hope that this paper provides the reader with a 
basic understanding of the molecular biology and 
concepts across the spectrum of the omics technologies. 
Clinical utility and application in sepsis may lead to a 
paradigm shift in diagnosis, management and our under-
standing of sepsis. Th   e traditional ﬂ  ow of genetic infor-
mation is from epigenome, genome and transcriptome to 
proteome and metabolome, but most studies focus on 
one space, thereby ignoring changes in other spaces. Th  e 
biology of human disease is complex; we must therefore 
submit that a multi  dimensional view involving the input 
Figure 4. An integrated analysis. Integrated analysis of multidimensional genomics, epigenomics and proteomics data to capture the interaction 
between genetics, gene expression and regulatory RNA as well as proteomics. The analysis will enable identifi  cation of critical pathways or 
biological processes that drive the perturbation across multiple genome-level spaces, and thus are critical for disease pathophysiology.
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understand  ing. Studying the inter  action and crosstalk of 
genomic information exchange between the epigenomic, 
genomic and proteomic space may assist in identifying 
core pathways that are continuously dysregulated, 
starting from epigenome to proteome (Figure 4).
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